Sonapax, pills 25mg 60pcs

Composition

>of 1 tablet contains: Active ingredient: Thioridazine hydrochloride-25 mgsupport substances: Corn starch, colloidal silicon dioxide (aerosil), lactose, gelatin, stearic acid, talc, sucrose, Arabian gum, cochineal red dye

Pharmacological action

Sonapax is a neuroleptic drug.

Inhibits dopamine and adrenergic transmission at the level of the reticular formation of the brain stem (mainly) and cortex.

It has an antipsychotic (noted after 10-14 days of use) and weak antidepressant effect.

It blocks H1-antihistamines and peripheral m-cholinergic receptors.

It has the most pronounced antihistamine and anticholinergic effect among all drugs from the group of neuroleptics.

Indications

Schizophrenia, including paranoid, schizoaffective disorders; psychosis, including involutional; psychosomatic disorders; depressive states accompanied by a sense of fear; withdrawal syndrome in chronic alcoholism, itching (severe, painful) in skin diseases, behavioral disorders (increased psychomotor activity) in children.

Contraindications

Hypersensitivity (including to phenothiazine derivatives), depression (acute condition), comatose states, pheochromocytoma, porphyria, hematopoietic insufficiency, I trimester and last week of pregnancy, children under 4 years of age.

Side effects

From the nervous system and sensory organs: Parkinsonism syndrome, dyskinesia, akathisia, drowsiness, apathy, irritability, depression, delirium, convulsive seizures, thermoregulation disorders.

From the cardiovascular system and blood (hematopoiesis, hemostasis): tachycardia, orthostatic hypotension, agranulocytosis, leukopenia, eosinophilia, pancytopenia, thrombocytopenic purpura.

Gastrointestinal disorders: constipation, cholestatic jaundice.

Skin disorders: allergic reactions, discoid lupus, photosensitization.

Other: hyper-or hypoglycemia, gynecomastia, menstrual disorders, decreased libido.

Interaction

Synergism of action with general anesthetics, opiates, barbiturates, ethanol, atropine.

Increases the hepatotoxic effect of antidiabetic drugs.

With amphetamine-acts antagonistically. With levodopa-reduces the antiparkinsonian effect.

Use with epinephrine – may lead to a sudden and pronounced decrease in blood pressure.

With guanethidine, it reduces the antihypertensive effect of the latter, but increases the effect of other antihypertensive agents, which increases the risk of significant orthostatic hypotension.

Reduces the effect of anti-coagulants. The effect of Sonapax can be weakened by anticonvulsants, cimetidine.

Quinidine-potentiates the cardiodepressive effect.

Ephedrine-helps paradoxically reduce blood pressure. Sympathomimetics-enhance the arrhythmogenic effect.

Probucol, astemizole, cisapride, disopyramide, erythromycin, pimozide, procainamide and quinidine contribute to an additional prolongation of the QT interval, which increases the risk of ventricular tachycardia.

Antithyroid medications increase the risk of agranulocytosis.

Reduces the effect of appetite suppressants (with the exception of fenfluramine).

Reduces the effectiveness of the emetic effect of apomorphine, increases its depressing effect on the central nervous system.

Increases the plasma concentration of prolactin and prevents the action of bromocriptine.

When combined with tricyclic antidepressants, maprotilin, MAO inhibitors, antihistamines, it is possible to prolong and enhance the sedative and anticholinergic effects.

With thiazide diuretics-increased hyponatremia.

With lithium preparations, a decrease in absorption in the gastrointestinal tract, an increase in the rate of excretion of lithium ions by the kidneys, an increase in the severity of extrapyramidal disorders, and early signs of lithium intoxication ( nausea and vomiting ) can be masked by the antiemetic effect of perphenazine.

When combined with beta-blockers, it increases the hypotensive effect, increases the risk of developing irreversible retinopathy, arrhythmias and tardive dyskinesia.

How to take, course of use and dosage

Inside. The dosage regimen is individual.

For adults:

• For acute psychoses, mania, schizophrenia and agitation depressions In outpatient settings-150-400 mg per day; in hospital-250-800 mg per day. Treatment usually begins with low doses of 25-75 mg per day, gradually increasing to the optimal therapeutic dose, which is usually reached within 7 days, and the antipsychotic effect is noted after 10-14 days. The course of treatment is several weeks. Maintenance daily dose: 75-200 mg once before bedtime. The drug should be discontinued gradually.
• In the treatment of the elderly, usually low doses are used: 30-100 mg per day.

For mental and emotional disorders:

• For mild disorders – 30-75 mg per day.
• For moderate disorders – 50-200 mg per day.

Start treatment with low doses, gradually increasing them to the optimal therapeutic dose.

For psychosomatic disorders,10-75 mg per day. To suppress severe itching, the dose of the drug is set individually and it should not exceed 200 mg.

For children:

• From 4 to 7 years – 10-20 mg per day. The frequency of reception is 2-3 times a day.
• From 8 to 14 years – 20-30 mg per day. The frequency of reception is 3 times a day.
• From 15 to 18 years – 30-50 mg per day. The frequency of reception is 3 times a day.

Overdose

Symptoms: drowsiness, confusion, urinary retention, disorientation, coma, areflexia, hyperreflexia, dry mouth, nasal congestion, postural hypotension, respiratory depression, convulsions, hypothermia.

Treatment is symptomatic, aimed at reducing absorption and accelerating the elimination of the drug. Gastric lavage with a solution of activated charcoal, laxatives (for example, magnesium sulfate).

Introduction of isotonic solutions. Monitoring the function of the cardiovascular and respiratory systems. If necessary, they consistently perform artificial ventilation of the lungs, monitor the function of the cardiovascular system, and prevent the development of metabolic acidosis. There is no specific antidote,

Special instructions

During treatment, it is necessary to monitor the morphological composition of the blood: refrain from using ethanol and engaging in potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Impact on the ability to drive vehicles and maintain machinery in motion:

Sonapax weakens motor coordination and reduces response, especially at the beginning of treatment, so during treatment with the drug, you should refrain from driving vehicles and servicing moving mechanisms.

Form of production

Dragees

Storage conditions

In a dry place, at a temperature not exceeding 25 °C

Shelf life

4 years

Active ingredient

Thioridazine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets